From Casetext: Smarter Legal Research

Hoffmann-La Roche Inc. v. Teva Pharms. USA, Inc.

United States Court of Appeals for the federal Circuit
May 21, 2012
2012-1131 (Fed. Cir. May. 21, 2012)

Opinion

2012-1131 2012-1195

05-21-2012

HOFFMANN-LA ROCHE INC., Plaintiff-Appellant, v. TEVA PHARMACEUTICALS USA, INC. AND TEVA PHARMACEUTICAL INDUSTRIES LTD., Defendants-Appellees. HOFFMANN-LA ROCHE INC., Plaintiff-Appellant, v. ACCORD HEALTHCARE INC. AND INTAS PHARMACEUTICAL LTD., Defendants-Appellees.


NOTE: This order is nonprecedential.


Appeal from the United States District Court for the District of New Jersey in case no. 09-CV-5283, Judge Esther Salas.

Appeal from the United States District Court for the District of New Jersey in case no. 11-CV-1192, Judge Esther Salas.

ON MOTION


ORDER

Hoffmann-La Roche Inc. moves to consolidate the above-captioned appeals. Teva Pharmaceuticals USA, Inc. et al. (Teva) oppose. Accord Healthcare Inc. et al. (Accord) oppose consolidation and move to stay appeal no. 2012-1195 pending appeal no. 2012-1131 stating they agree to be bound by this court's decision in 2012-1131. Hoffmann-La Roche replies and consents to a stay of 2012-1195. Hoffmann-La Roche moves for an extension of time, until May 9, 2012, to file its opening brief in 2012-1131. Teva opposes. Hoffmann La Roche replies. Hoffmann La Roche also moves without opposition for an extension of time to file its opening brief in 2012-1195.

Hoffmann La Roche also moved to consolidate these appeals with Hoffmann-La Roche v. Roxane Labs, No. 2012-1132, but this court subsequently granted Hoffmann LaRoche's motion to voluntarily dismiss that appeal.

Upon consideration thereof,

IT IS ORDERED THAT:

(1) The motion to consolidate is denied.
(2) Appeal no. 2012-1195 is stayed pending issuance of the mandate in appeal no. 2012-1131. Within 14 days thereof, Hoffmann La Roche and Accord are directed to inform this court concerning how they believe 2012-1195 should proceed.
(3) A copy of this order will be forwarded to the merits panel in appeal no. 2012-1131.
(4) Hoffmann La Roche's motion for an extension of time is granted.
(5) Teva shall calculate the due date for its response brief from the date of filing of this order.
(6) Hoffmann La Roche's motion for an extension of time in 2012-1195 is moot in light of the stay.

FOR THE COURT cc: Brian D. Coggio, Esq.

Jeffer Ali, Esq.

Kenneth G. Schuler, Esq.

Michael R. Dzwonczyk, Esq.
s25

______________

Jan Horbaly

Clerk


Summaries of

Hoffmann-La Roche Inc. v. Teva Pharms. USA, Inc.

United States Court of Appeals for the federal Circuit
May 21, 2012
2012-1131 (Fed. Cir. May. 21, 2012)
Case details for

Hoffmann-La Roche Inc. v. Teva Pharms. USA, Inc.

Case Details

Full title:HOFFMANN-LA ROCHE INC., Plaintiff-Appellant, v. TEVA PHARMACEUTICALS USA…

Court:United States Court of Appeals for the federal Circuit

Date published: May 21, 2012

Citations

2012-1131 (Fed. Cir. May. 21, 2012)